Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2018659 | 0.73 | ALDH1A1 (0.36) | ALDH1A1TDP1TSHRGAA | |
| Trifluoroacetic Acid SCHEMBL28340710 | 0.72 | MCL1 (0.41) | ALDH1A1KDM4EPOLBEPHX1 | |
| SCHEMBL2016710 | 0.71 | KMT2A (0.38) | ALDH1A1POLBGAA | |
| SCHEMBL18602384 | 0.70 | MCL1 (0.54) | ALDH1A1KDM4EPOLBTSHRL3MBTL1 | |
| SCHEMBL8956928 | 0.70 | MEN1 (0.37) | ALDH1A1TDP1KDM4EPOLBTSHR | |
| SCHEMBL24453194 | 0.70 | MEN1 (0.38) | ALDH1A1TDP1KDM4EPOLB | |
| Trifluoroacetic Acid SCHEMBL31245497 | 0.70 | DNM1 (0.44) | ALDH1A1KDM4EMAPK1 | |
| Hydrochloric Acid SCHEMBL2021168 | 0.70 | KMT2A (0.37) | ALDH1A1TDP1POLBGAA | |
| SCHEMBL2019891 | 0.69 | CNR1 (0.42) | ALDH1A1TDP1 | |
| SCHEMBL14813162 | 0.69 | KMT2A (0.39) | ALDH1A1POLBTP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160180-A1 | Cannabinoid Receptor Ligands | ASTRAZENECA AB (SE) | 2011-06-30 | — | — | US | disclosed |
| EP-2190838-A1 | CANNABINOID RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2010-06-02 | — | — | EP | disclosed |
| US-20090062251-A1 | Novel Compounds 002 | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| WO-2009024819-A1 | CANNABINOID RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062251-A1 | Novel Compounds 002 | OPRL1, OPRK1, OPRM1 | ALDH1A1 517/4885TDP1 3699/4885KDM4E 2054/4885 |
| US-20110160180-A1 | Cannabinoid Receptor Ligands | CNR1, CNR2, OPRL1 | ALDH1A1 2240/4885TDP1 4423/4885KDM4E 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.